Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14346585 | 0.84 | MAPT (0.45) | MAPTALDH1A1MEN1KMT2APDK1 | |
| SCHEMBL19409680 | 0.81 | ALDH1A1 (0.43) | MAPTALDH1A1MEN1KMT2APDK1 | |
| SCHEMBL5483 | 0.79 | ALDH1A1 (0.51) | MAPTALDH1A1MEN1KMT2APDK1 | |
| SCHEMBL237380 | 0.78 | MAPT (0.60) | MAPTALDH1A1MEN1KMT2A | |
| SCHEMBL2375356 | 0.78 | MAPT (0.60) | MAPTALDH1A1MEN1KMT2A | |
| SCHEMBL8891623 | 0.78 | MAPT (0.60) | MAPTALDH1A1MEN1KMT2A | |
| SCHEMBL4221 | 0.78 | — | — | |
| SCHEMBL5364 | 0.78 | MAPT (0.49) | MAPTALDH1A1MEN1KMT2APDK1 | |
| SCHEMBL11788383 | 0.77 | PPM1B (0.38) | ALDH1A1KMT2APDK1TSHR | |
| SCHEMBL13279907 | 0.76 | MAPT (0.47) | MAPTALDH1A1MEN1KMT2APDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11767312-B2 | Phthalazinone compound, and preparation method therefor and medical use thereof | GENENTECH, INC. (US) | 2023-09-26 | — | — | US | disclosed |
| US-11767312-B2 | Phthalazinone compound, and preparation method therefor and medical use thereof | GENENTECH, INC. (US) | 2023-09-26 | — | — | US | disclosed |
| US-20230242510-A1 | PHTHALAZINONE COMPOUND, AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | SHANGHAI JEMINCARE PHARMACEUTICALS CO LTD (CN) | 2023-08-03 | — | — | US | disclosed |
| US-20230242510-A1 | PHTHALAZINONE COMPOUND, AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | SHANGHAI JEMINCARE PHARMACEUTICALS CO LTD (CN) | 2023-08-03 | — | — | US | disclosed |
| WO-2023125928-A1 | MENIN INHIBITOR AND USE THEREOF | 成都先导药物开发股份有限公司 | 2023-07-06 | — | — | WO | disclosed |
| US-20230131252-A1 | PHTHALAZINONE COMPOUND, AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | SHANGHAI JEYOU PHARMACEUTICAL CO., LTD. (CN) | 2023-04-27 | — | — | US | disclosed |
| US-20230131252-A1 | PHTHALAZINONE COMPOUND, AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | SHANGHAI JEYOU PHARMACEUTICAL CO., LTD. (CN) | 2023-04-27 | — | — | US | disclosed |
| EP-4166550-A1 | PHTHALAZINONE COMPOUND, AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | Shanghai Jemincare Pharmaceuticals Co., Ltd. (CN) | 2023-04-19 | — | — | EP | disclosed |
| US-20220339146-A1 | CYANO-SUBSTITUTED CYCLIC HYDRAZINE DERIVATIVE AND APPLICATION THEREOF | E-NITIATE BIOPHARMACEUTICALS (HANGZHOU) CO., LTD (CN) | 2022-10-27 | — | — | US | disclosed |
| US-20190031665-A1 | DERIVATIVES OF PYRROLOIMIDAZOLE OR ANALOGUES THEREOF WHICH ARE USEFUL FOR THE TREATMENT OF INTER ALIA CANCER | EMCURE PHARMACEUTICALS LIMITED (IN) | 2019-01-31 | — | — | US | disclosed |
| CN-105061188-A | Preparation method of 4,4-difluorocyclohexanecarboxylic acid | SHANGHAI AQBIOPHARMA CO LTD | 2015-11-18 | — | — | CN | disclosed |
| US-8772277-B2 | Nitrogen-containing heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-07-08 | — | — | US | disclosed |
| US-20130072467-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2013-03-21 | — | — | US | disclosed |
| WO-2013018929-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-02-07 | — | — | WO | disclosed |
| US-8044206-B2 | Nitrogen—containing heterocyclic derivatives having 2,6-disubstituted styryl | ASTELLAS PHARMA INC. (JP) | 2011-10-25 | — | — | US | disclosed |
| CN-100516040-C | Nitrogenous heterocyclic derivative having 2,6-disubstituted styryl | ASTELLAS PHARMA INC KOTOBUKI S (JP) | 2009-07-22 | — | — | CN | disclosed |
| US-20070099956-A1 | Nitrogen-containing heterocyclic derivatives having 2, 6-disubstituted styryl | ASTELLAS PHARMA INC. AND KOTOBUKI PHARMACEUTICAL CO., LTD. | 2007-05-03 | — | — | US | disclosed |
| EP-1602645-A1 | NITROGENOUS HETEROCYCLIC DERIVATIVE HAVING 2,6-DISUBSTITUTED STYRYL | Astellas Pharma Inc. (JP) | 2005-12-07 | — | — | EP | disclosed |
| WO-2005014519-A1 | PROCESS FOR THE PREPARATION OF GEMINAL DIFLUOROALKANES | HONEYWELL SPECIALTY CHEMICALS SEELZE GMBH (DE) | 2005-02-17 | — | — | WO | disclosed |
| US-3931288-A | ANTIINFLAMMATORY, ANTIRHEUMATIC | HOFFMANN-LA ROCHE INC. (US) | 1976-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130072467-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | ESRRA, ESRRB, ESR2 | MAPT 3689/4885ALDH1A1 785/4885MEN1 2128/4885 |
| US-20220339146-A1 | CYANO-SUBSTITUTED CYCLIC HYDRAZINE DERIVATIVE AND APPLICATION THEREOF | WNK1, STK35, CDK1 | MAPT 715/4885ALDH1A1 3352/4885MEN1 1867/4885 |
| US-20190031665-A1 | DERIVATIVES OF PYRROLOIMIDAZOLE OR ANALOGUES THEREOF WHICH ARE USEFUL FOR THE TREATMENT OF INTER ALIA CANCER | IDO1, IDO2, TDO2 | MAPT 3786/4885ALDH1A1 946/4885MEN1 4094/4885 |
| US-11767312-B2 | Phthalazinone compound, and preparation method therefor and medical use thereof | CYP17A1, AR, NR5A1 | MAPT 2509/4885ALDH1A1 490/4885MEN1 425/4885 |
| US-20070099956-A1 | Nitrogen-containing heterocyclic derivatives having 2, 6-disubstituted styryl | SCN1B, CACNA1B, SCN2A | MAPT 964/4885ALDH1A1 2549/4885MEN1 3647/4885 |
| US-20230131252-A1 | PHTHALAZINONE COMPOUND, AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | CYP17A1, AR, NR5A1 | MAPT 2509/4885ALDH1A1 490/4885MEN1 425/4885 |
| US-20230242510-A1 | PHTHALAZINONE COMPOUND, AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | CYP17A1, AR, NR5A1 | MAPT 2509/4885ALDH1A1 490/4885MEN1 425/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.